AstraZeneca and Hitachi agree to collaborate on COPD onset and prognosis

AstraZeneca Corporation
AstraZeneca and Hitachi agree to collaborate on COPD onset and prognosis
AstraZeneca Co., Ltd. (Head office: Kita-ku, Osaka, President: Stefan Voxstrum, AstraZeneca) is Hitachi, Ltd. (Head office: Chiyoda-ku, Tokyo, President and CEO: Toshiaki Higashihara) , Hitachi) and the joint research of ArtDeco Study: A joint research on the history of the development of chronic obstructive pulmonary disease (COPD) and the prognosis after the onset.
In this joint research, we will analyze COPD risk factors based on Hitachi’s tens of thousands of health checkup data (history of smoking, spirometry lung function test data, cough and sputum questionnaires, etc.). In this joint research, AstraZeneca will create a research design and analysis protocol from the knowledge about COPD, and Hitachi will analyze the data using advanced analysis technology and AI.
There are few reports of studies in Japan that have been followed up for a long time about the prognosis of COPD patients until the onset of COPD, and there is limited evidence in Japan. If this study identifies COPD risk factors and characteristic parameters until healthy individuals develop COPD, it will be possible to identify people with a high probability of onset and to improve lifestyle and promote early visits aimed at preventing onset It becomes. The results of this joint research will be published next spring.
Although the prevalence of COPD in Japanese over 40 years old is estimated to be 8.6% and the number of patients is estimated to be 5.3 million (1), according to a survey by the Ministry of Health, Labor and Welfare, the number of patients actually receiving treatment is approximately 26. There are only 10,000 people (2). In other words, despite being COPD, more than 5 million people are untreated and many patients are unaware, not properly diagnosed, or properly treated even if diagnosed correctly It is thought that it has not received. COPD is a progressive lung disease that can be fatal. In addition, reduced physical activity due to COPD or comorbidities is likely to violate the patient’s healthy life span, so early detection and treatment are necessary.
AstraZeneca respects the value of “Patient First” and is making various efforts to improve patients’ QOL. Through the use of data obtained from this joint research, we will make an effort to contribute to the early start of treatment and improvement of healthy life expectancy for COPD patients.
Hitachi is also developing services that utilize cutting-edge IT such as AI in the healthcare field, and is energetically implementing various initiatives such as demonstration experiments. With this joint research as the first step, we will deepen our knowledge of big data analysis related to health and medical care, continue to make advanced efforts in health and medical care, and promote the development and provision of innovative IT services through collaborative creation. I will continue.
that’s all
*****
About chronic obstructive pulmonary disease (COPD)
COPD is a progressive disease in which shortness of breath occurs due to obstruction of airflow in the lungs and is exhausted (3). COPD affects an estimated 384 million people worldwide and is predicted to be the third leading cause of death by 2020 (3,4). Improving respiratory function, reducing exacerbations, and managing daily symptoms such as shortness of breath are important treatment goals for COPD (2).
About AstraZeneca
AstraZeneca is a science-oriented global biopharmaceutical company that discovers, develops, manufactures and markets prescription drugs in three key areas: oncology, cardiovascular / renal / metabolic disorders, and respiratory・ I am engaged in sales activities. The company operates in over 100 countries and its innovative medicine is used by many patients around the world. For more information, follow http://www.astrazeneca.com or follow us on Twitter @AstraZeneca (English only).
In Japan, we focus on oncology, cardiovascular / metabolic / gastrointestinal diseases, and respiratory diseases to make further contributions to patient health and medical development. For more information about our company, please visit
https://www.astrazeneca.co.jp.
About Hitachi
Hitachi is focusing on the Social Innovation Business that combines OT (Operational Technology), IT (Information Technology) and products. In fiscal 2018, consolidated revenue was 9,480.6 billion yen, and the number of employees at the end of March 2019 was approximately 296,000. Hitachi contributes to the three values ​​of customer social value, environmental value, and economic value by providing digital solutions utilizing Lumada in the five fields of mobility, life, industry, energy, and IT. For details, see the Hitachi website (http://www.hitachi.co.jp).
References
1 Epidemiological Research NICE Study (2001)
http://www.gold-jac.jp/copd_facts_in_japan
2 Ministry of Health, Labor and Welfare Demographic Statistics 3 GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. [Online]. Available at: http://goldcopd.org Last accessed: May 2019.
4 Usmani O, Capstick T, Chowhan H, et al. Inhaler choice guideline. March 2017 [Online]. Available at:
https://www.guidelines.co.uk/respiratory/inhaler-choice-guideline/252870.article Last accessed: May 2019.


For more information about this release(Japanese):

https://prtimes.jp/main/html/rd/p/000000158.000024308.html




  • Comment ( 0 )

  • Trackbacks are closed.

  1. No comments yet.